Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.

ABSTRACT: Melanoma is a severe and life-threatening malignancy derived from melanocytes. The traditional treatment for melanoma could not sustain satisfactory outcomes long term; however, the recent immune checkpoint treatment has made a breakthrough in these problems. Nivolumab is a representative immune checkpoint treatment, and this PD-1-targeted therapy has evolutionally developed and improved the clinical outcome in a recent decade. On the other hand, the clinical application of immune checkpoint treatment presents clinicians with novel questions, especially how to obtain additional efficacy and overcome the disadvantage by using this treatment. To answer these problems, we first investigated the distribution of PD-L1 in various organs to clarify the organs most affected by anti-PD-1 antibody t

SUBMITTER: Saito R 

PROVIDER: S-EPMC7920420 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature